Clareo Health | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy
Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Bologna
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed FL grade I-II according to the REAL/WHO classification (from initial diagnosis made prior to starting FMR therapy);
FLIPI 3 or more
Central pathology review confirming the FL grade I-II diagnosis and CD20 positivity, and no evidence/evidence with an infiltration \<25% of FL in bone marrow;
The first part of the treatment of FL must have been 4 cycles of standard FM chemotherapy (fludarabine 25 mg/m2/day on days 1 to 3 and mitoxantrone 10 mg/m2 on day 1) in combination with rituximab (375 mg/m2); Complete remission (CR), unconfirmed complete remission (CRu), partial response, and non-responder according to the International Workshop Response Criteria for NHL described by Cheson et al after four cycles of FMR. CT scans of the neck, thorax, abdomen, and pelvis and PET total body must have been performed within 3 weeks after the last dose of the last course of FMR;
Patients 18-years-of-age or older at time of accrual;
WHO performance status (PS) of 0 to 2 within 1 week of accrual;
Absolute neutrophil count (ANC) more than 1.5 x 109/L within 1 week of accrual;
Hemoglobin (Hgb) more than10 g/dL within 1 week of accrual;
Platelets more than 150 x 109/L within 1 week of accrual.
Written informed consent obtained according to local guidelines
You may not be if
Presence of any other malignancy or history of prior malignancy except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma;
Prior radioimmunotherapy, radiation therapy, or any other NHL therapy;
Presence of gastric, central nervous system (CNS), or testicular lymphoma at first diagnosis;
Histological transformation of low-grade NHL;
Known seropositivity for hepatitis C virus (HCV) or hepatitis B surface antigen (HbsAg);
Known history of HIV infection;
Abnormal liver function: total bilirubin \> 1.5 x ULN or ALT \> 2.5 x ULN within 1 week of accrual;
Abnormal renal function: serum creatinine \> 2.0 x ULN within 1 week of accrual;
Known hypersensitivity to murine or chimeric antibodies or proteins;
G-CSF or GM-CSF therapy within two weeks (or four weeks if pegylated) prior to screening laboratory sampling;
Concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study;
Male and female patients of child-bearing potential unwilling to practice effective contraception during the study and unwilling or unable to continue contraception for 12 months after their last dose of study treatment;
Female patients who are pregnant or are currently breastfeeding;
Treatment with investigational drugs less than 4 weeks before the planned Day 1 or nonrecovery from the toxic effects of such therapy;
Surgery less than 4 weeks before the planned Day 1 or nonrecovery from the side effects of such surgery;
Concurrent corticosteroid use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment;
Unwillingness or inability to comply with the protocol.
